
In a multicenter, retrospective study of 51 patients with recurrent or metastatic adenoid cystic carcinoma (R/M ACC), lenvatinib demonstrated an overall response rate of 21.7% and a disease control rate of 73.9%. Median overall survival was 16.1 months. Grade ≥3 adverse events included hypertension (25.5%), stomatitis (17.6%), and fatigue (15.7%). These findings affirm lenvatinib’s real-world efficacy but signal the need for monitoring toxicities.
Like
Save
Share